Study: Testing a new medicine for knee osteoarthritis

Study summary

Knee osteoarthritis (OA) is the most common cause of knee pain in older adults. But there are no effective treatments which can both reduce pain and the rate at which the disease progresses.

Recent research, however, suggests that treatments which prevent bone loss may be effective at reducing pain and joint damage in people with knee OA.

This study is trying to find out if a one off administration of a new drug treatment which prevents bone loss, given as an injection under the skin, is effective at relieving pain in people with painful knee OA and reducing structural damage to the knee.

If  this treatment is effective, it could make a real difference to people living with knee osteoarthritis.

Who can take part?

You may be eligible to take part if you are aged 50 years or over and have knee osteoarthritis

What will the research involve?

The treatment involves a one-off injection under the skin and taking vitamin D and calcium supplements.

You will be screened for eligibility, which includes height, weight, vital signs, knee x-ray and blood tests. A magnetic resonance imaging (MRI) scan of your knee will be taken at the start and end of the study.

You will be followed up at 3 and 6 months and questionnaires will be completed at each visit.

Where will the research take place?

Study appointments will be held at Salford Royal and The Wellcome Trust Manchester Clinical Research Facility.

Study References

Ethics approved references for this study are listed below

  • REC: 17/NW/0262

For further information, please contact the research team:

Tel: 0161 306 0545 / 0547
Email: ROAM@manchester.ac.uk

 

Skip to content